← Eichor
Study identifier: NCT06931626 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Condition: Small Cell Lung Cancer  ·  Sponsor: Nerviano Medical Sciences

PhasePhase 1
Planned participants10
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.

This description comes directly from the study's public registry record.

Talk to the study team

Domenico Roberti  ·  +39 0331-581111  ·  clinicaltrials@nervianoms.com

Always discuss trial participation with your own doctor first.

Locations (3)

OSF Saint Francis Medical CenterPeoria, Illinois, United StatesRecruiting
Massachusetts General HospitalBoston, Massachusetts, United StatesRecruiting
Tennessee Oncology, PLLCNashville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06931626